See every side of every news story
Published loading...Updated

Osivax Raises Strategic Funding

Summary by FinSMEs
Osivax, a Lyon, France-based biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating respiratory viruses, closed its Series B financing, raising €10M from new and existing investors. Backers included Meiji Seika Pharma. The company intends to use the funds to accelerate preclinical and clinical development of its broad-spectrum influenza vaccine candidates. Led by […] The post Osivax Raises $10M…
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

All
Left
Center
Right
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

FinSMEs broke the news in on Tuesday, March 4, 2025.
Sources are mostly out of (0)

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.